慢性阻塞性肺疾病合并肌少症的研究进展
Research Progress of Chronic Obstructive Pulmonary Disease Complicated with Sarcopenia
DOI: 10.12677/ACM.2023.134954, PDF,   
作者: 张 颖*：华北理工大学研究生学院，河北 唐山；韩书芝#：河北省人民医院老年呼吸内科，河北 石家庄
关键词: 慢性阻塞性肺疾病；肌少症；发病机制；COPD； Sarcopenia； Pathogenesis
摘要: 慢性阻塞性肺疾病是呼吸系统最常见的慢性疾病，肌少症是其重要合并症，肌少症严重影响慢性阻塞性肺疾病的进展和预后。本文章对慢性阻塞性肺疾病合并肌少症的流行病学、诊断标准、发病机制及干预措施进行综述，以此提高临床医生对慢性阻塞性肺疾病合并肌少症的认识，期望改善疾病的转归和预后。
Abstract: Chronic obstructive pulmonary disease (COPD) is the most common chronic disease of the respira-tory system, and sarcopenia is an important complication. Sarcopenia seriously affects the progres-sion and prognosis of COPD. This article reviews the epidemiology, diagnostic criteria, pathogenesis and intervention measures of chronic obstructive pulmonary disease complicated with sarcopenia, so as to improve clinicians’ understanding of chronic obstructive pulmonary disease complicated with sarcopenia, and to improve the outcome and prognosis of the disease.
文章引用：张颖, 韩书芝. 慢性阻塞性肺疾病合并肌少症的研究进展[J]. 临床医学进展, 2023, 13(4): 6820-6825. https://doi.org/10.12677/ACM.2023.134954

参考文献

[1] Vogelmeier, C.F., Román-Rodríguez, M., Singh, D., et al. (2020) Goals of COPD Treatment: Focus on Symptoms and Exacerbations. Respiratory Medicine, 166, Article ID: 105938. [Google Scholar] [CrossRef] [PubMed]
[2] Halpin, D.M.G., Criner, G.J., Papi, A., et al. (2021) Global Initia-tive for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 203, 24-36. [Google Scholar] [CrossRef] 
[3] 陈可铭, 徐胜前, 徐月辰, 等. 肌少症-骨量减少/骨质疏松与类风湿关节炎患者合并脊柱骨质疏松性骨折发生的相关性研究[J]. 中国骨质疏松杂志, 2020, 26(7): 1018-1022+1082.
[4] Okumura, S., Kaido, T., Hamaguchi, Y., et al. (2015) Impact of Preoperative Quality as Well as Quantity of Skeletal Muscle on Survival after Resection of Pancreatic Cancer. Surgery, 157, 1088-1098. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, L.K., Woo, J., Assantachai, P., et al. (2020) Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medi-cal Directors Association, 21, 300-307. [Google Scholar] [CrossRef] [PubMed]
[6] Smith, M.C. and Wrobel, J.P. (2014) Epidemiology and Clinical Impact of Major Comorbidities in Patients with COPD. International Journal of Chronic Obstructive Pulmonary Dis-ease, 9, 871-888. [Google Scholar] [CrossRef] 
[7] Zhu, B., Wang, Y., Ming, J., et al. (2018) Disease Burden of COPD in China: A Systematic Review. International Journal of Chronic Obstructive Pulmonary Disease, 13, 1353-1364. [Google Scholar] [CrossRef] 
[8] Tunsupon, P. and Mador, M.J. (2017) The Influence of Body Composition on Pulmonary Rehabilitation Outcomes in Chronic Obstructive Pulmonary Disease Patients. Lung, 195, 729-738. [Google Scholar] [CrossRef] [PubMed]
[9] Cruz-Jentoft, A.J., Landi, F., Schneider, S.M., et al. (2014) Prevalence of and Interventions for Sarcopenia in Ageing Adults: A Systematic Review. Report of the Interna-tional Sarcopenia Initiative (EWGSOP and IWGS). Age and Ageing, 43, 748-759. [Google Scholar] [CrossRef] [PubMed]
[10] Demircioğlu, H., Cihan, F.G., Kutlu, R., et al. (2020) Frequency of Sarcopenia and Associated Outcomes in Patients with Chronic Obstructive Pulmonary Disease. Turkish Journal of Med-ical Sciences, 50, 1270-1279. [Google Scholar] [CrossRef] [PubMed]
[11] Perrot, L., Greil, A., Boirie, Y., et al. (2020) Prevalence of Sarcopenia and Malnutrition during Acute Exacerbation of COPD and after 6 Months Recovery. European Journal of Clinical Nu-trition, 74, 1556-1564. [Google Scholar] [CrossRef] [PubMed]
[12] Sepúlveda-Loyola, W., Osadnik, C., Phu, S., et al. (2020) Diag-nosis, Prevalence, and Clinical Impact of Sarcopenia in COPD: A Systematic Review and Meta-Analysis. Journal of Cachexia, Sarcopenia and Muscle, 11, 1164-1176. [Google Scholar] [CrossRef] [PubMed]
[13] Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., et al. (2010) Sarcopenia: European Consensus on Definition and Diagnosis: Report of the European Working Group on Sarcopenia in Older Peo-ple. Age and Ageing, 39, 412-423. [Google Scholar] [CrossRef] [PubMed]
[14] Cruz-Jentoft, A.J., Bahat, G., Bauer, J., et al. (2019) Sarcopenia: Re-vised European Consensus on Definition and Diagnosis. Age and Ageing, 48, 16-31. [Google Scholar] [CrossRef] [PubMed]
[15] Cruz-Jentoft, A.J., Bahat, G., Bauer, J., et al. (2019) Sarcopenia: Re-vised European Consensus on Definition and Diagnosis. Age and Ageing, 48, 601. [Google Scholar] [CrossRef] [PubMed]
[16] Sanders, K.J., Kneppers, A.E., Van De Bool, C., et al. (2016) Cachexia in Chronic Obstructive Pulmonary Disease: New Insights and Therapeutic Perspective. Journal of Cachexia, Sarcopenia and Muscle, 7, 5-22. [Google Scholar] [CrossRef] [PubMed]
[17] Lewis, A., Lee, J.Y., Donaldson, A.V., et al. (2016) Increased Expression of H19/miR-675 Is Associated with a Low Fat-Free Mass Index in Patients with COPD. Journal of Cachexia, Sarcope-nia and Muscle, 7, 330-344. [Google Scholar] [CrossRef] [PubMed]
[18] Sinden, N.J. and Stockley, R.A. (2010) Systemic Inflammation and Comorbidity in COPD: A Result of “Overspill” of Inflammatory Mediators from the Lungs? Review of the Evidence. Thorax, 65, 930-936. [Google Scholar] [CrossRef] [PubMed]
[19] Byun, M.K., Cho, E.N., Chang, J., et al. (2017) Sarcopenia Corre-lates with Systemic Inflammation in COPD. International Journal of Chronic Obstructive Pulmonary Disease, 12, 669-675. [Google Scholar] [CrossRef] 
[20] Yakabe, M., Ogawa, S., Ota, H., et al. (2018) Inhibition of Interleukin-6 Decreases Atrogene Expression and Ameliorates Tail Suspension-Induced Skeletal Muscle Atrophy. PLOS ONE, 13, e0191318. [Google Scholar] [CrossRef] [PubMed]
[21] Broekhuizen, R., Wouters, E.F., Creutzberg, E.C., et al. (2006) Raised CRP Levels Mark Metabolic and Functional Impairment in Advanced COPD. Thorax, 61, 17-22. [Google Scholar] [CrossRef] [PubMed]
[22] 赵云静, 杨晓蕾, 尹粉英, 等. 慢性阻塞性肺疾病合并肌少症的发病机制[J]. 中国老年保健医学, 2023, 21(1): 110-113.
[23] 谢灿辉, 黄丹, 黎东明. 慢性阻塞性肺疾病合并肌少症的研究进展[J]. 中国医学创新, 2022, 19(26): 179-183.
[24] Donaldson, A.V., Maddocks, M., Martolini, D., et al. (2012) Muscle Function in COPD: A Complex Interplay. International Journal of Chronic Obstructive Pulmonary Dis-ease, 7, 523-535. [Google Scholar] [CrossRef] 
[25] Kent, B.D., Mitchell, P.D. and Mcnicholas, W.T. (2011) Hypoxemia in Patients with COPD: Cause, Effects, and Disease Progression. International Journal of Chronic Obstructive Pulmonary Disease, 6, 199-208. [Google Scholar] [CrossRef] 
[26] Spruit, M.A., Singh, S.J., Garvey, C., et al. (2013) An Official Amer-ican Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 188, e13-e64.
[27] Attwell, L. and Vassallo, M. (2017) Response to Pulmonary Rehabilitation in Older People with Physical Frailty, Sarcopenia and Chronic Lung Disease. Geriatrics (Basel, Switzerland), 2, 9. [Google Scholar] [CrossRef] [PubMed]
[28] Jones, S.E., Maddocks, M., Kon, S.S., et al. (2015) Sarcopenia in COPD: Prevalence, Clinical Correlates and Response to Pulmonary Rehabilitation. Thorax, 70, 213-218. [Google Scholar] [CrossRef] [PubMed]
[29] De Blasio, F., Di Gregorio, A., De Blasio, F., et al. (2018) Malnutrition and Sarcopenia Assessment in Patients with Chronic Obstructive Pulmonary Dis-ease According to International Diagnostic Criteria, and Evaluation of Raw BIA Variables. Respiratory Medicine, 134, 1-5. [Google Scholar] [CrossRef] [PubMed]
[30] Rondanelli, M., Klersy, C., Terracol, G., et al. (2016) Whey Protein, Amino Acids, and Vitamin D Supplementation with Physical Activity Increases Fat-Free Mass and Strength, Functionality, and Quality of Life and Decreases Inflammation in Sarcopenic Elderly. The American Journal of Clinical Nutrition, 103, 830-840. [Google Scholar] [CrossRef] [PubMed]
[31] Van Wetering, C.R., Hoogendoorn, M., Broekhuizen, R., et al. (2010) Efficacy and Costs of Nutritional Rehabilitation in Muscle-Wasted Patients with Chronic Obstructive Pulmonary Disease in a Community-Based Setting: A Prespecified Subgroup Analysis of the INTERCOM Trial. Journal of the American Medical Directors Association, 11, 179-187. [Google Scholar] [CrossRef] [PubMed]
[32] Hostrup, M., Reitelseder, S., Jessen, S., et al. (2018) Be-ta(2)-adrenoceptor Agonist Salbutamol Increases Protein Turnover Rates and Alters Signalling in Skeletal Muscle after Resistance Exercise in Young Men. The Journal of Physiology, 596, 4121-4139. [Google Scholar] [CrossRef] 
[33] Lee, P., Birzniece, V., Umpleby, A.M., et al. (2015) Formoterol, a Highly β2-Selective Agonist, Induces Gender-Dimorphic Whole Body Leucine Metabolism in Humans. Metabolism: Clinical and Experimental, 64, 506-512. [Google Scholar] [CrossRef] [PubMed]
[34] Toledo, M., Penna, F., Oliva, F., et al. (2016) A Multifactorial Anti-Cachectic Approach for Cancer Cachexia in a Rat Model Undergoing Chemotherapy. Journal of Cachexia, Sarco-penia and Muscle, 7, 48-59. [Google Scholar] [CrossRef] [PubMed]
[35] Barberan-Garcia, A., Rodríguez, D.A., Blanco, I., et al. (2015) Non-Anaemic Iron Deficiency Impairs Response to Pulmonary Rehabilitation in COPD. Respirology (Carlton, Vic), 20, 1089-1095. [Google Scholar] [CrossRef] [PubMed]

为你推荐